Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

3 of the Top Big Pharma Stocks to Buy Now

By Chris Lau, InvestorPlace Contributor Jan 15, 2019

Big pharma stocks are getting good coverage from JPMorgan's healthcare event. Here are three undervalued pharmaceutical stocks to buy now.

Microbot’s Products in Focus After Huge Gains by MBOT Stock

By Chris Lau, InvestorPlace Contributor Jan 15, 2019

We explain the surge of MBOT stock and describe the products that could lead to much higher prices for Microbot stock in the future.

Here’s Why Shopify Stock Should Have Another Great Quarter

By Chris Lau, InvestorPlace Contributor Jan 15, 2019

Shopify stock trades at a premium for good reason: merchant additions keep growing. That should be enough for beats this quarter.

Why Sarepta Therapeutics Stock Is Starting to Shine Again

By Chris Lau, InvestorPlace Contributor Jan 11, 2019

SRPT stock rebounded nicely from its sub-$100 low last month. More upside is possible as the Sarepta ramps up an important study.

Is It Time to Sell Celgene Stock After the Bristol-Myers Squibb Offer?

By Chris Lau, InvestorPlace Contributor Jan 8, 2019

Celgene shareholders who bought CELG stock at lows last year started 2019 on a bright note; Bristol-Myers is buying it for $74 billion.

Axsome Therapeutics: Do Not Buy AXSM Stock After Its Monster Rally

By Chris Lau, InvestorPlace Contributor Jan 8, 2019

No longer a penny stock, Axsome Therapeutics (AXSM) surged past $8 a share on news that its AXS-05 treatment affected a 17.2-point drop in patients on the Montgomery-Asbert Depression Rating Scale. But is it a buy?